Lloryn Hubbard is a distinguished leader in clinical research, dedicated to advancing health equity and ensuring diverse populations are represented in clinical trials. As the Director of Clinical Trial Diversity and Patient Voice at Daiichi Sankyo, she drives initiatives that enhance inclusivity in clinical trials and fostering meaningful engagement with underrepresented communities.
Previously, Lloryn served as Head of Patient Diversity at PPD a part of Thermo Fisher Scientific, where she provided strategic oversight of the company’s clinical trial health equity efforts. She led a team of specialists focused on optimizing drug development strategies to improve representation and outcomes for diverse patient populations.
Recognized for her contributions to the field, Lloryn was named the 2024 Clinical Trial Visionary of the Year by DTC Perspectives. She holds a Bachelor of Arts in Biology and Cultural Anthropology from Seattle University and is currently based in Oakland, CA.